Healthcare resource utilization and costs for 12 months after initial prescription were compared. Univariate descriptive analyses were performed for baseline and outcome variables and compared using appropriate tests. Risk adjustment compared HCRU between RxOP and NoRxOP cohorts for the postindex period. Results: Of 27,599 eligible patients, RxOP patients (n = 18,819) were younger, less likely to be male, more likely to reside in southern United States and to have Preferred Provider Organization health plans, and had lower comorbidity index scores, compared with NoRxOP patients (n = 8,780). RxOP patients were less likely to have nonpainrelated comorbidities and more frequently diagnosed with pain-related comorbidities.
Unmatched and propensity-matched RxOP patients experienced higher HCRU and costs in all subcategories (total, inpatient, outpatient ED, physician, pharmacy, other outpatient settings). Opioid abuse frequency was low in patients with common diagnoses/procedures within 3 months before initial prescription (0.48%). Average time to abuse was < 1 year (201 days). Conclusion: Most patients were prescribed opioids initially during ED/inpatient visits and incurred higher HCRU than those not prescribed opioids. Among those with diagnosed opioid abuse after initiating opioids, time to diagnosis was rapid (range: 14 to 260 days) for patients with common diseases and procedures. &
INTRODUCTION
Over the past 2 decades, health professionals have been addressing the issue of undertreated pain more aggressively through the increase in prescription opioids to treat cancer-related and noncancer pain. This has resulted in a simultaneous increase in opioid abuse in the United States. 1, 2 The doses at which opioid analgesics are sometimes abused can lead to respiratory depression and death. 3 In 2009, there were over 2 million opioid-dependent adults in the United States, and opioid misuse has become a leading cause of death nationwide. 4 According to the Substance Abuse and
Mental Health Services Administration (SAMHSA) in 2009, there were 35 emergency department (ED) visits, 161 patient reports of drug abuse or dependence, and 461 reports of nonmedical uses of opioid analgesics for every unintentional opioid-related overdose death. 5 Use of prescription opioids in the United States increased 402% overall from 1997 to 2007, 6 and in the medically insured population, 7 to 8 patients per 10,000 have shown evidence of diagnosed opioid abuse. 7 Additionally, diagnosed abusers with multiple comorbidities incurred healthcare expenses which were 8 times higher than those without diagnosed abuse. 8 Patients with diagnosed opioid abuse were 6.7 times more likely to be hospitalized and 2.3 times more likely to have ED visits. 9 Researchers are becoming increasingly aware of the instrumental role that ED settings play in the prescription of opioid medications. EDs prescribe 29% of all opioid medications administered and are the largest ambulatory source for opioids.
10 Inappropriate prescribing of opioid medications in the ED setting can occur and includes the prescription of long-acting opioids to treatment-naive individuals. 11 EDs also often handle the consequences of inappropriate prescription opioid use. An estimated 305,900 ED visits were related to the nonmedical use of opioid analgesics in 2008, a 111% increase from the 144,600 visits in 2004. 12 However, while EDs have been well studied in the distribution of American opioid medications, 8- 14 In this study, healthcare resource utilization (HCRU) and costs between patients who were prescribed opioids vs. those without an opioid prescription during an ED or inpatient visit were compared. Additionally, the rate of diagnosed opioid abuse by specific diseases and procedures was determined after the first opioid prescription.
METHODS

Data Source and Study Sample
A retrospective cohort analysis was performed using data from the linked MarketScan The index date was defined as the date of the initial opioid prescription for the prescription opioid user (RxOP) cohort and the random date between the first ED/inpatient admission and the end of the identification period for those not prescribed opioids in an ED/ inpatient setting (NoRxOP cohort).
Baseline variables were calculated during the 12 months prior to the index date, otherwise known as the pre-index period, and outcome variables were calculated during the 12 months after the index date (ie, postindex period).
Patients who were 12 years of age or older on the index date with continuous health plan enrollment, including medical and pharmacy benefits, from the preindex period through the postindex period were selected. Subjects were excluded from the study if they were prescribed opioid medications during the 12-month pre-index period.
Cohort Assignments
In addition to the comparison between RxOP and NoRxOP patients, the diagnosed opioid abuse after prescription cohort was created using a population of patients diagnosed with certain diseases a or who had certain procedures b during the 3 months preceding the first opioid prescription in an emergency room (ER)/inpatient setting during the identification period. Qualified participants were required to be identified as diagnosed opioid abusers if they had evidence of diagnosis of opioid abuse after the first opioid prescription date. Top 10 conditions or procedures prior to opioid abuse have been grouped into different categories: cardiovascular/metabolic conditions (hypertension not otherwise specified (NOS); benign hypertension; uncontrolled type II diabetes mellitus; hyperlipidemia; coronary atherosclerosis); mental health (depressive disorder); general health/routine screening (malaise and fatigue; routine gynecologic examination, mammogram); opioid-related conditions (opioid dependence-continuous, opioid dependence-unspecified, opioid poisoning); and pain conditions (lumbago, pain in limb, abdominal pain unspecified site, chest pain). Procedures prior to opioid abuse included cardiac procedures (percutaneous transluminal coronary angioplasty or coronary atherosclerosis, left heart cardiac catheterization, coronary arteriogram-2 catheterization, left heart angiocardiogram, noncoronary angiogram), orthopedic procedures (lymphatic structure biopsy, lumbar/lumbosacral fusion lateral and posterior, total hip and knee replacements, refusion of lumbar post), gynecologic surgery (low cervical c-section, c-section, total abdominal hysterectomy, total abdominal hysterectomy NOS), general surgery (laparoscopic cholecystectomy), and other procedures (drug rehabilitation/detoxification).
Outcome Variables
Similar to pre-index costs, total, inpatient, outpatient ED, physician visit, other outpatient, and pharmacy costs were calculated during the 12-month follow-up period based upon the amount paid by the health plan on relevant claims and net cost of any patient contribution (eg, copayment). Costs were expressed in 2010 U.S. dollars and were adjusted using the medical care a Cardiovascular/metabolic conditions, mental health, general health/routine screening, opioid-related conditions, pain conditions. b Cardiac procedure, orthopedic procedures, gynecologic surgery, general surgery, others. component of the U.S. CPI. Postindex HCRU included the number of inpatient, outpatient ED, and physician office visits, plus binary indicators of having at least one visit.
The frequency of diagnosed opioid abuse was defined as the number of patients detected with certain diseases c or procedures (Table 4) in the 3 months prior to the index date (first opioid prescription date in ED/inpatient), number of diagnosed opioid abusers after index date, and number of days from first opioid prescription to first opioid abuse diagnosis.
Statistical Analysis
Univariate descriptive analyses were performed for all baseline and outcome variables. Percentages and standard deviations were calculated for dichotomous variables, and P values were calculated using the chisquared test. Means and standard deviations were calculated for continuous variables, and P values were calculated using the student's t-test.
To adjust the baseline differences in demographic and clinical characteristics between the 2 cohorts, risk adjustment was performed using 1:1 propensity score matching (PSM) to compare all postindex healthcare costs and utilization between the RxOP and NoRxOP cohorts. Variables incorporated in matching were patients' age, gender, geographic region, health plan type, comorbidities, HCRUs, and costs in the pre-index period. The PSM method created very closely balanced study cohorts that appeared similar on a large number of measures. In essence, the PSM methodology sought to mimic a randomized experiment by constructing a control group under the assumption of the ignorable treatment assignment, that is, individuals were randomly assigned to treatment and control groups, given a set of observed covariates. The propensity score modeled the clinical decision-making process; patients were matched if their propensity scores were within AE0.01 units of each other.
Multivariate analysis was performed by using generalized linear models, where log link and gamma distributions were used for cost outcomes, negative binomial distribution was used for count variables such as number of healthcare utilization visits, and logistic link was used for binary outcomes such as having at least one visit.
RESULTS
Study Sample
After applying inclusion and exclusion criteria, a total of 27,599 patients were eligible for the study (Figure 1 ). Sixty-eight percent of the patients (RxOP; n = 18,819) were prescribed opioids (mean age = 54.5 years), and 32% (NoRxOP; n = 8,780) were not (mean age = 55.1 years). Among RxOP patients (n = 18,819), 17% (n = 3,226) were prescribed opioids in the ED setting, and 83% (n = 15,593) were prescribed opioids in inpatient settings. However, among all patients observed in the sample with an ER visit, 56% were prescribed opioids. Among all observed patients with an inpatient admission, 71% were prescribed opioids.
Among patients in the RxOP cohort, the majority of patients (96%, n = 18,031) were prescribed immediaterelease opioids, and 4% (n = 788) were prescribed extended-release opioids. Among all patients who were prescribed an opioid (N = 18,819), the long-acting opioid prescription rate was slightly higher in the ED (6.5%) vs. inpatient setting (3.7%).
Demographics and Clinical Characteristics
RxOP patients were younger (54.5 vs. 55.1; P = 0.0293), less likely to be male (35.6% vs. 43.0%; P < 0.0001), more likely to reside in the southern region of the United States (86.6% vs. 78.2%; P < 0.0001), and more likely to have a PPO health plan (55.1% vs. 49.8%; P < 0.0001) compared with NoRxOP patients (Table 1) .
Additionally, RxOP patients were less likely to have Elixhauser Index scores of at least 2% (18.5% vs. 19.5%; P = 0.0430) and had lower CCI (1.10 vs. 1.31; P < 0.0001) and CDS scores (4.54 vs. 4.88; P < 0.0001) than NoRxOP patients.
RxOP patients were less likely to have many of the nonpain-related comorbid conditions studied, including other substance abuse (2.6% vs. 4.4%; P < 0.0001), nonopioid poisoning (0.8% vs. 1.7%; P < 0.0001), psychiatric disorders (13.8% vs. 17.6%; P < 0.0001), endocarditis (0.2% vs. 0.4%; P = 0.0040), gastrointestinal bleeding (11.8% vs. 13.0%; P = 0.0044), cirrhosis/ chronic or acute liver disease (2.9% vs. 3.7%, P = 0.0004), alcoholic hepatitis (0.1% vs. 0.2%; P = 0.0012), and pancreatitis (0.9% vs. 1.6%, P < 0.0001). Exceptions included sexually transmitted diseases (6.8% vs. 5.7%; While RxOP patients were generally less likely to have nonpain-related comorbid conditions, they were more often found with every pain-related comorbid condition studied (Table 1) . Common conditions included arthritis (42.6% vs. 35.6%; P < 0.0001), low back pain (23.7% vs. 17.4%; P < 0.0001), other back/ neck disorders (21.8% vs. 16.2%; P < 0.0001), and cancer (12.1% vs. 10.8%; P = 0.0014).
Baseline Costs and Utilization
RxOP patients were less likely to have inpatient (18.3% vs. 78.2%; P < 0.0001) and ED visits (36.1% vs. 47.3%; P < 0.0001), but more likely to have physician visits (95.3% vs. 93.9%; P < 0.0001) in the pre-index period. Correspondingly, RxOP patients had a lower number of average inpatient (0.26 vs. 0.98; P < 0.0001) and ED visits (0.68 vs. 0.84; P < 0.0001) but greater physician visits (9.03 vs. 8.44; P < 0.0001).
RxOP patients had lower total ($17,120 vs. $25,569; P < 0.0001) and inpatient costs ($4,462 vs. $13,131; P < 0.0001) but higher outpatient physician visit costs than NoRxOP patients ($832 vs. $760; P < 0.0001).
Postindex Descriptive Outcomes
In the unmatched cohorts, it was more common for RxOP patients to have inpatient (100% vs. 23.1%, P < 0.0001), outpatient ED (45.2% vs. 29.8%; P < 0.0001), and physician visits (93.4% vs. 90.2%; P < 0.0001), and RxOP patients utilized more of these 2 types of visits compared with NoRxOP patients (Table 2 ). RxOP patients also had higher average healthcare costs in all subcategories, including total ($42,829 vs. $16,861; P < 0.0001), inpatient ($26,484 vs. $5,199; P < 0.0001), outpatient ED ($520 vs. $360; P < 0.0001), and physician visit costs ($833 vs. $682; P < 0.0001), pharmacy ($3,042 vs. $2,898; P = 0.0406), and other outpatient costs ($11,954 vs. $7,722; P < 0.0001).
Postindex-Adjusted Outcomes
After PS matching and controlling for baseline demographic and clinical differences using the generalized linear model, results were slightly different in magnitude from the unadjusted values but did not change the postindex descriptive healthcare cost and utilization pattern, as illustrated in Figure 2 . Demographic and clinical results of RxOP and NoRxOP cohorts after PSM are outlined in Table 3 . After matching, no demographic or clinical variable differed significantly between the 2 cohorts. Among the 5,099 matched pairs, the RxOP cohort had more inpatient (1.58 vs. 0.36; P < 0.0001), physician office (10.17 vs. 8.96; P < 0.0001), and ED visits (1.12 vs. 0.67; P < 0.0001) than matched NoRxOP patients in the follow-up period.
RxOP users had significantly higher healthcare costs in terms of total healthcare ($49,766 vs. $19,875; P < 0.0001), inpatient ($30,659 vs. $6,104; P < 0.0001), outpatient ED ($627 vs. $408; P < 0.0001), outpatient physician visit ($892 vs. $778; P < 0.0001), outpatient pharmacy ($3,583 vs. $3,199; P = 0.0074), and other outpatient costs ($14,011 vs. $9,387; P < 0.001) compared with NoRxOP patients (Figure 3 ).
Diagnosed Opioid Abuse After Initiation of Prescription Opioids in ED/Inpatient Setting
Of the total eligible patients, 110 individuals (0.5%) were diagnosed with opioid abuse after an average of 201 days from their first opioid prescription (Table 4) . By disease, the 7 of 18 patients with opioid-related conditions (38.9%) were diagnosed with opioid abuse after an average of 14 days from first opioid prescription, followed by mental health conditions (8 of 313, or 2.6%, diagnosed after 201 days), pain conditions (56 of 6,048, or 0.9%, diagnosed after 167 days), cardiovascular/metabolic conditions (43 of 8,969, or 0.5%, diagnosed after 142 days), and general health/routine screening (14 of 2,906, or 0.5% diagnosed after 260 days). By procedure, 5 of 161 patients with cardiac procedures (3.1%) were diagnosed with opioid abuse after an average of 167 days. Of those patients with orthopedic procedures (n = 51), gynecologic surgery (n = 39), general surgery (n = 26), and others (n = 0), no diagnosed opioid abuse was detected after the first opioid prescription.
DISCUSSION
This observational study, using a linked U.S. commercial administrative claims database from 2006 to 2010, compared healthcare costs and utilization of patients who initiated prescription opioids vs. those who did not in ED and inpatient hospital settings.
Results indicated that initial opioid prescribing remains a common practice in ED and inpatient settings. In our study, a greater proportion of opioid prescriptions were made in the inpatient hospital setting (71%) than the ED (56%).
There appears to be an inverse correlation between baseline clinical characteristics and cost/utilization outcomes for RxOP and NoRxOP patients. While RxOP patients have lower comorbidity scores (Elixhauser, CDS, CCI) when compared with NoRxOP patients, their postindex healthcare utilization (higher inpatient, physician office, ED visits) and costs (adjusted total, outpatient physician visit, outpatient ED, outpatient pharmacy, other outpatient costs) were higher. However, after PSM, baseline differences between cohorts adjusted well. In the postmatch samples, patients in both cohorts had similar demographic characteristics and comorbidities. Some previous studies have demonstrated that certain comorbidities such as depression, pain, and workers' compensation status are significant risk predictors for high healthcare costs and utilizations. 18, 19 In our study, trauma, gastrointestinal bleeding, and psychiatric disorder were the 3 most common nonpain-related comorbidities observed during the baseline period. Arthritis, low back pain, and other back/neck disorders were the most common pain-related baseline comorbidities. Although identifying predictors of high healthcare costs and utilizations were not one of the objectives in this study, future research will be necessary to explore the significance of these factors. In our study, a lower frequency of prescription opioid users was found living in the Northeast and Midwest/ North Central United States regions (2.1% and 9.3%, respectively), and most patients prescribed opioids resided in the south (86.55%). This study provides evidence supporting the consistency in geographic opioid prescribing tendencies, as reported in previous studies. Olsen et al. 13 found that U.S. physicians in the Northeast and Midwest were significantly less likely to prescribe opioids than those working in the south and west and that patients in these regions had lower odds of being prescribed an opioid medication (OR = 0.60 and 0.75). 11 In the recent study by McDonald et al., 20 Appalachia, western, and southern states were found to have the highest opioid prescribing rates. Number of available physicians was the strongest predictor of opioid prescription patterns. Unfortunately, the number of physicians and surgeons was not available in the database used for this study; therefore, further analysis will be needed to confirm the risk factors for opioid prescribing patterns, using alternative data. This study also examined the frequency and time to diagnosed opioid abuse by selected diagnosis and procedure designations. Overall, the frequency of diagnosed opioid abuse in patients with common diagnoses/ procedures was low (0.5%); however, the average time to diagnosed abuse was < 1 year (201 days). As the use of ICD-9-CM codes could only determine diagnosed opioid abuse, the generalization of results for undiagnosed opioid abusing populations may be invalid. Rates of prescription opioid abuse in patients from pain clinics have ranged from 0% to 90%, which demonstrates Figure 3 . Adjusted cost outcomes for RxOP and NoRxOP cohorts. RxOP, prescription opioid; NoRxOP, no prescription opioid; ED, emergency department. *P value < 0.0001, **P value < 0.0010. study population heterogeneity and variations in defining prescription opioid abuse. 21 Common cardiovascular/metabolic diseases and general health screenings are unlikely causes to initiate opioid use, and correspondingly, patients in these categories had low frequencies of diagnosed opioid abuse. While 2.6% of those with a mental health condition were later diagnosed with opioid abuse in this study, the sample size of patients with mental disorders was small (n = 313), and further research would be necessary to determine any connections. Although the sample sizes were small, there was a lack of diagnosed opioid abuse related to recent clinical procedures, suggesting that patients prescribed opioid medications after common clinical procedures are less likely to become diagnosed opioid abusers.
Due to the nature of the commercial claims database, the study results only represent the patients who were continuously insured in the commercial insurance plan. Uninsured and Medicaid patients, who have been demonstrated to have a high incidence of obtaining prescription opioids and percentage of chronic opioid misuse, were not included in this study. Due to the retrospective design of the study, 22 it is difficult to be certain of causal relationships. Due to this limitation, only the association between the variables of interest and the outcomes could be calculated. Additionally, residual confounding from unmeasured variables (such as treatment patterns, socioeconomic status, or disease severity) could have affected associations between various exposure variables and resulting health outcomes. The presence of a claim for a filled opioid prescription does not indicate whether the medication was actually taken as prescribed. Diversion still exists in situations where patients obtain opioids outside of the studied healthcare settings, and claims of diagnosed abuse only capture those patients whose physicians document their abuse in the claims system. Therefore, total opioid abuse would likely be underestimated. Despite these limitations, the use of a large claims database and a 4-year observation period in this study contribute to its nationally representative implications. This study also uses recent data, which is important in a population with increasing, rather than stationary, opioid abuse rates.
